Korro Bio, Inc.

As the year wraps up, we look forward to taking some time to recharge and prepare for 2025!   Next year, we’ll continue our mission to develop innovative RNA therapies to improve the lives of those facing debilitating and life-threatening diseases. We’re excited for what’s to come and grateful for your continued support.   Wishing you a joyful and restful holiday season!

The #KorroKrew was honored to join our friends and partners in the Alpha-1 community and Alpha-1 Foundation for the 2024 A1F Virtual Walk! Thanks to everyone who put together this fun and important event raising awareness and funds for Alpha-1 Antitrypsin Deficiency (#AATD).   Check out the impact we made together in the recap video: https://lnkd.in/eb8cu_ND #Alpha1Awareness #A1FWalk #Alpha1Foundation

What do cephalopods – such as squids and octopus – have in common with the discovery of new medicines? A documentary by students at MIT Graduate Program in Science Writing has an answer: RNA editing.   Inspired by cephalopods’ ability to edit their RNA at any given moment, scientists at Korro Bio are working to harness the RNA editing technology to develop medicines for both rare and highly prevalent diseases. The approach aims to correct the genetic information itself instead of focusing on addressing the symptoms. Learn more about how the approach works in this short film: https://lnkd.in/g-G998P8 #RNAediting #RNAresearch #GeneEditing #KorroBio

Attending the Oppenheimer Movers in Rare Disease Summit on Thursday?   Don’t miss our CEO & President, Ram Aiyar, Ph.D., at 3:40 PM ET participate in the panel discussion “Recent Progress in RNA Editing.” #RNAEditing #GeneticMedicine #OppenheimerAndCo Oppenheimer & Co. Inc.

Please join us in welcoming Christina Broomes, MBA, to Korro Bio as Vice President, Technical Operations!  With over 20 years of experience in biotechnology, Christina specializes in clinical and commercial manufacturing, GMP facility development, and CMC strategy. Her superpower is leading teams to successfully deliver genetic medicines to patients, and we’re excited to have her on the #KorroKrew to do just that! #KorroBio #TechnicalOperations 

Korro’s management will be participating in several upcoming investor conferences.   Piper Sandler 36th Annual Healthcare Conference: CEO & President Ram Aiyar, Ph.D. and CMO Kemi Olugemo, MD, FAAN, will participate in a fireside chat on Tuesday, Dec. 3, at 4:00 PM ET. CFO Vineet Agarwal will also participate in 1x1 investor meetings.   7th Annual Evercore ISI HealthCONx Conference: Dr. Aiyar will participate in a fireside chat on Wednesday, Dec. 4, at 7:30 AM ET. Mr. Agarwal and Dr. Olugemo will also participate at the conference.   Citi’s 2024 Global Healthcare Conference: Dr. Aiyar, Mr. Agarwal, and Dr. Olugemo will participate in 1x1 investor meetings on Thursday, Dec. 5.   Oppenheimer & Co. Inc. Movers in Rare Disease Summit: Dr. Aiyar will participate in the panel “Recent Progress on RNA Editing” on Thursday, Dec. 12, at 3:40 PM ET. Mr. Agarwal will also be participating at the conference.    You can access the live webcast of the Piper Sandler and Evercore fireside chats on our website’s “Events & Presentations” page: https://lnkd.in/g4n4jJqk   #KorroBio #RNAediting #GeneticMedicine #PiperSandler #Evercore #CitiBank #OppenheimerAndCo

Attending Jones Virtual Genetic Medicine Day on Monday, November 25?   Join us from 1:00–2:00 PM ET as our CEO & President, Ram Aiyar, Ph.D. participates in a panel discussion focused on the role of RNA editing in Alpha-1 Antitrypsin Deficiency (#AATD).   #RNAEditing #GeneticMedicine JonesTrading

We are pleased to share that we have received approval from the Australian Bellberry Human Research Ethics Committee and clearance from the Australian Therapeutic Goods Administration to begin our Phase 1/2a clinical study (REWRITE) of KRRO-110 for Alpha-1 Antitrypsin Deficiency (#AATD). We expect to dose the first study participant in the first quarter of 2025, with an interim readout anticipated in the second half of 2025 and completion of the Phase 1/2a study expected in 2026. We’re excited to advance KRRO-110 to the clinic to evaluate its best-in-class potential and look forward to sharing updates in 2025. Read the full release: https://lnkd.in/esES5HVm

Korro Bio CEO and president, Ram Aiyar, Ph.D., will be presenting at the Jefferies London Healthcare Conference on Tuesday, November 19, at 8:00 AM GMT.   Alongside Dr. Aiyar, our CFO, Vineet Agarwal, and our CMO, Kemi Olugemo, MD, FAAN, will also be participating in the event. This is an exciting opportunity to learn more about Korro Bio's innovative approach to RNA editing for rare and prevalent diseases.   Tune in to the live webcast: https://lnkd.in/g4n4jJqk   We look forward to sharing our progress in advancing a new class of genetic medicines. #KorroBio #RNAEditing #HealthcareInnovation #GeneticMedicine #JefferiesHealthcare

Today, we reported our third quarter 2024 financial results and recent progress. We are pleased to highlight our recent achievements, including a regulatory filing submission for a first-in-human clinical study of KRRO-110 for alpha-1 antitrypsin deficiency (AATD) in Australia and formation of the AATD clinical advisory board to support KRRO-110’s entry into the clinic. Our partnership with Novo Nordisk enables us to advance the discovery and development of new genetic medicines, with the initial target of treating cardiometabolic diseases. We strengthened our leadership team with the appointment of Jeffrey Cerio as General Counsel and enhanced our Board of Directors with the appointment of Katharine Knobil, M.D.   Our strong cash position provides runway into 2H'26 to fund multiple value-creating milestones, including the anticipated completion of the KRR0-110 FIH study and progression of additional pipeline candidates. Read the full press release here: https://lnkd.in/eDS53Y5q #KorroBio